Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Biomarker Discovery, Validation & Assay Development
Are you currently facing high IND failure rates, unreliable preclinical safety signals, and limited translational data from conventional models? NHP models at Creative Biolabs help you obtain validated, clinically relevant biomarkers and robust assay development through advanced NHP models, multiomics profiling, and targeted mass spectrometry. We bridge the gap between bench and bedside, delivering the data required for confident clinical progression.
Creative Biolabs' NHP Models Bridging Preclinical and Clinical Biomarker Gaps!
Human-relevant NHP models are essential for discovering and validating translational biomarkers that predict human safety and efficacy, overcoming the inherent biological and immunological limitations of rodent models.
Overview of NHP Applications
What Are Our Research Areas?
Cross-Species Immune Mapping is a critical preclinical discipline centered on precisely characterizing the differences and, more importantly, the similarities between animal model and human immune systems at the cellular and molecular level. This research background is necessitated by the increasing complexity of immunotherapies, which target specific cells, receptors, or signaling pathways. Effective translational science requires moving beyond simple histological or bulk data to generate high-resolution atlases. This involves mapping cell-type compositions, gene expression profiles, and gene regulatory networks across various tissues (e.g., bone marrow, spleen, lymph nodes) in NHPs and humans to create a validated molecular blueprint. This approach ensures that a therapeutic's mechanism of action observed in the NHP model is truly orthologous to the mechanism expected in humans.
Why Choose Us?
Leveraging the NHP model is not merely a preference but a regulatory and scientific necessity for many advanced therapies.
- Genetic and Immunological Similarities: NHPs share up to 93% genomic homology with humans, providing immune system architecture and disease progression kinetics that are highly analogous to human patients, unlike rodent models.
- Clinical Translational Relevance: Biomarkers discovered in NHPs exhibit a significantly higher predictive value for human response, directly reducing translational risk.
- Physiological Complexity: NHPs possess complex organ systems, including reproductive, neurological, and cardiovascular systems, allowing for the comprehensive assessment of systemic toxicity and biodistribution.
Distributed under Unsplash License, from Unsplash.
Key Applications
NHP models are uniquely suited for complex biomarker campaigns that require human-like physiological and immunological responses.
- Acute Injury & Disease Modeling: Utilizing multiomics to rapidly characterize systemic damage and validate multi-analyte panels (protein, metabolite, lipid) for conditions like acute radiation injury, trauma, or sepsis, enabling the development of rapid molecular diagnostics.
- Immunogenicity & Biologic Response: Accurately modeling ADA and NAb generation for biologics, assessing the risk of immunotoxicity, and monitoring complex events like Cytokine Release Syndrome (CRS) in cell and gene therapy.
- PD & Target Engagement: Monitoring PD markers (e.g., receptor occupancy via flow cytometry, expression levels of target mRNA/protein) in relevant tissues and blood, providing early proof-of-concept for drug mechanism before human trials.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides an end-to-end workflow, ensuring seamless transition from in vivo study design to definitive data reporting. The following are key service capability entries:
| Service Capability | Corresponding Application Area |
| Biological Collection & Biobanking | Custom Collection Services and NHP Bio-specimen Bank for longitudinal and repeat sampling of donor-matched cohorts (blood, serum, PBMCs) with full cold-chain management. |
| Safety & Toxicology | Interpreting and comparing multi-omic data from NHP and human samples. |
| Bioanalysis & Biomarker Analysis | Proteomics & Metabolomics Pipelines (Multi-Omics) for unbiased biomarker discovery, followed by Small Molecule Quantitation (LC-MS/MS) and Large Molecule Quantitation (ELISA, MSD) for assay validation. |
| Pharmacology & Efficacy | Advanced Therapy Efficacy Studies (AAV, CAR-T) and Disease Model Development (Cardiovascular, Neurological) to validate biomarkers against functional disease endpoints. |
Translational Impact
Choosing the NHP model and our advanced multiomics-driven approach provides a demonstrable return on investment by mitigating late-stage failure. NHP studies are proven to provide more reliable early proof of concept, leading to an estimated 70%+ concordance with human clinical data in key areas of pharmacology and safety. Our expertise enables the early detection of immune responses and toxicity saving significant capital that would otherwise be spent on non-viable candidates. Furthermore, NHP biodistribution data is often explicitly required by regulatory bodies for advanced therapy IND submissions, making this translational step non-negotiable for success.
Frequently Asked Questions
Q: What is the resolution and sensitivity of Creative Biolabs' multiomics platform for biomarker discovery?
A: Our multiomics platform leverages high-resolution mass spectrometry, providing unprecedented depth and quantitative accuracy across the serum, tissue, and cell proteome and metabolome. This high sensitivity is crucial for detecting low-abundance, early-stage disease or toxicity markers that traditional immunoassays might miss, ensuring robust discovery from minimal NHP sample volumes.
Q: What is your strategy for validating a discovered biomarker panel before moving to a clinical assay?
A: Our approach is translational: we move from unbiased Multi-Omics discovery in NHP tissue/serum to a targeted validation phase using highly specific platforms (e.g., LC-MS/MS or multiplex ELISA/MSD). We statistically confirm the performance of the panel across multiple doses and time points in the NHP model before advising on a validated clinical-grade assay.
Q: Why is the NHP model still necessary for my study when cost-effective rodent models are available?
A: While rodent models are useful for initial screening, they often fail to predict human response due to key differences in drug metabolism (DMPK) and immunology. For complex endpoints like immunogenicity, systemic toxicity, and CNS/cardiovascular safety, the NHP's evolutionary proximity to humans makes it the gold standard for preclinical data, minimizing the risk of a disastrous failure during your Phase I trial.
Contact Us
Creative Biolabs stands ready to deliver the high-quality, translational data required to de-risk your drug development pipeline. We combine expert NHP model stewardship with state-of-the-art Multi-Omics and Bioanalysis services to deliver predictive biomarker panels for safety and efficacy. Reach out to our dedicated team of translational biology specialists to discuss your specific project needs and receive a tailored quote.